# Kotak Alternate Asset Managers

> Kotak Alternate Asset Managers is a VC fund backing Health Care. See 39 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Mumbai, India
- Total investments: 39
- Last investment: Jun 2026
- Lead investor: 79%
- Fund size: $1.3B
- Last fund: Mar 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kotak-investment-advisors-ltd
- X (Twitter): https://www.twitter.com/kotakbankltd
- Website: http://www.privateequityfund.kotak.com
- Facebook: https://www.facebook.com/kotakbank

Kotak Alternate Asset Managers is a VC fund in Mumbai focused on Health Care and Biotechnology. Kotak Investment Advisors focuses exclusively on managing the alternate assets business of the Kotak Mahindra Group.

## Contacts

5 contacts available for Kotak Alternate Asset Managers. Shizune tracks 7 team members at Kotak Alternate Asset Managers. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kotak-investment-advisors?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4M–$12M |
| Debt Financing | $3.5M–$134M |
| Private Equity | $7.3M–$142M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 33% |
| Biotechnology | 7 | 18% |
| Manufacturing | 6 | 15% |
| Medical | 5 | 13% |
| Health Diagnostics | 5 | 13% |

42 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 11 | 28% |
| Series A | 7 | 18% |
| Debt Financing | 7 | 18% |
| Series B | 3 | 8% |
| Post-IPO Debt | 3 | 8% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 30 | 77% |
| United States | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Eshwar Karra | CEO | 7 | https://shizune.co/investors/profile/eshwar-karra |
| Rajeev Saptarshi | Chief Operating Officer | 0 | https://shizune.co/investors/profile/rajeev-saptarshi |
| Ramakrishna K. V. | Team Member | 0 | https://shizune.co/investors/profile/ramakrishna-k-v |
| Alroy Lobo | CEO | 0 | https://shizune.co/investors/profile/alroy-lobo |
| Lakshmi Iyer | Chief Executive Officer | 0 | https://shizune.co/investors/profile/lakshmi-iyer-2b3c |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vishwa Samudra Group | Vishwa Samudra Group is a diversified multinational business conglomerate focused on integrating ecology, economic growth, and social responsibility through sustainable infrastructure, energy, real estate, and technology-driven development initiatives. | $37.7M | Debt Financing | Jun 02, 2026 |  |
| Cellogen Therapeutics | Cellogen Therapeutics is a biotech company that is currently working on developing revolutionary cell therapy-based solutions. It treats a variety of hematological malignancies, solid tumors, and hemoglobinopathies using modern cellular engineering tools and gene therapy. | $2.1M | Seed | May 18, 2026 |  |
| Lloyds Metals And Energy | Lloyds Metals And Energy is an iron manufacturing company. It expanded by installing a waste heat recovery based 30 mw co generation captive power plant using waste heat from kiln off gasses generated from the kilns while manufacturing sponge iron. | $78.3M | Post-IPO Debt | May 14, 2026 |  |
| Zeroharm | Zeroharm is a wellness products company that supplies nutritional supplement products. | $7.2M | Series A | Feb 18, 2026 |  |
| Avammune Therapeutics | Avammune Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Avammune is developing a multimodal approach to modulate the STING pathway to treat cancer. Their multimodal approach employs a combination of engineered viruses and small molecules. | $12M | Series A | May 07, 2025 |  |
| Ace Designers | Ace Designers is the flagship company of the Ace Micromatic Group. The company was started in 1979 as a design consultancy firm by three CMTI engineers. Initially, the team created product ideas for a variety of machine tools, including specialized equipment. Ace entered the manufacturing sector in 1982 with a line of special purpose importsubstitution machines for the internal combustion engine valve industry. | $141.9M | Private Equity | Apr 30, 2025 |  |
| Ace Designers | Ace Designers is the flagship company of the Ace Micromatic Group. The company was started in 1979 as a design consultancy firm by three CMTI engineers. Initially, the team created product ideas for a variety of machine tools, including specialized equipment. Ace entered the manufacturing sector in 1982 with a line of special purpose importsubstitution machines for the internal combustion engine valve industry. | $141.9M | Private Equity | Apr 30, 2025 |  |
| Ahammune Biosciences | Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Our current program is on the depigmenting disorder, Vitiligo. | $5M | Series A | Sep 25, 2024 |  |
| Nutrabay | Nutrabay is a D2C multi-brand nutrition store that provides an online platform to sell nutritional supplements. Its products include proteins, whey proteins, mass gainers, amino acids, creatine, multivitamins, fish oil, herbs, and many more. | $5M | Series A | Sep 02, 2024 |  |
| Matrix Pharma | The purpose of the pharmaceutical matrix industry is to create a platform to build a robust API business that can support organic and inorganic growth. | $172.9M | Venture - Series Unknown | Jun 11, 2024 |  |

10 of 39 investments shown.

## Co-investors
- [Elevation Capital](https://shizune.co/investors/profile/elevation-capital-6e8a) — VC Fund, 4 deals together
- [1Crowd](https://shizune.co/investors/profile/1crowd) — VC Fund, 2 deals together
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund, 2 deals together
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund, 2 deals together
- [Capital 2B](https://shizune.co/investors/profile/capital-2b) — VC Fund, 2 deals together
- [LVX Ventures](https://shizune.co/investors/profile/letsventure) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in India](https://shizune.co/investors/biotech-vc-funds-india)
- [Biotech Investors in India](https://shizune.co/investors/biotech-investors-india)
- [Biotechnology Investors in India](https://shizune.co/investors/biotechnology-investors-india)
- [Biotechnology VC Funds in India](https://shizune.co/investors/biotechnology-vc-funds-india)
- [Life Science Investors in India](https://shizune.co/investors/life-science-investors-india)
- [Life Science VC Funds in India](https://shizune.co/investors/life-science-vc-funds-india)

## FAQ

### What does Kotak Alternate Asset Managers invest in?

Kotak Alternate Asset Managers invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Private Equity and Series A stage. Most of the 39 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Kotak Alternate Asset Managers's check size?

Kotak Alternate Asset Managers typically joins rounds of $4M–$12M at Series A, $3.5M–$134M at Debt Financing and $7.3M–$142M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kotak Alternate Asset Managers participates in.

### How do I contact Kotak Alternate Asset Managers?

Public channels for Kotak Alternate Asset Managers include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kotak Alternate Asset Managers?

The team at Kotak Alternate Asset Managers includes Eshwar Karra (CEO), Rajeev Saptarshi (Chief Operating Officer) and Ramakrishna K. V. (Team Member), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co